24/7 Wall Street
18 May 2026, 11:35 UTC · 3d ago
Source · https://247wallst.com/investing/2026/05/18/7-healthcare-ai-stocks-under-50-with-huge-upside-potential/
Read source
Search tags
Story key points
5 claims · impact-rated
Hims & Hers Health faces unresolved FDA and securities lawsuits regarding compounded GLP-1s and a Q1 2026 EPS miss of nearly 397%. — Regulatory and legal threats to core product lines combined with a massive earnings miss create significant downside risk.
-0.80Tempus AI reported 83% YoY revenue growth in Q4 2025 and provided 2026 revenue guidance of $1.59 billion. — Strong top-line growth and positive EBITDA flip suggest a successful transition to scalability.
+0.60Doximity's FY2027 revenue guidance ($664M-$676M) implies a meaningful growth deceleration compared to FY2026 revenue of $644.86M. — Projected slowdown in revenue growth typically leads to multiple compression for growth-oriented tech stocks.
-0.40Nurix Therapeutics is advancing its lead asset bexobrutideg into a Phase 3 study starting mid-2026 with $540.73 million in cash runway. — Progressing to Phase 3 with a strong cash position reduces immediate bankruptcy risk and increases the probability of a clinical catalyst.
+0.40Schrodinger's operating cash flow swung from positive $144 million to negative $14.83 million year over year. — A sharp reversal in cash flow indicates increasing burn and potential need for dilutive financing.
-0.30Impact vectors
5 dimensions · 9 clusters
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Ticker attribution
Model heads
Strong revenue growth and positive EBITDA flip, though offset by high debt and dilution risks.
Positive analyst ratings and promising clinical pipeline, despite a significant drop in Q1 revenue.
Strong cash flow and AI tool adoption, though facing potential growth deceleration in FY2027.
Mentioned in the context of a validating $2.3 billion acquisition of Ajax Therapeutics.
Validation from the Ajax acquisition and upcoming AI product launch, despite meaningful cash burn.
Mentioned as a deepening partner for Tempus AI and collaborator for Nurix Therapeutics.
Mentioned as a deepening partner for Tempus AI.
Mentioned as a branded GLP-1 partner for Hims & Hers.
Mentioned as a deepening partner for Tempus AI (Daiichi Sankyo).
Explicitly mentioned as being excluded from a top 10 stocks list by a prominent analyst.
Raised revenue guidance and international growth are countered by a massive EPS miss and ongoing lawsuits.
Mentioned as a collaborator for Nurix Therapeutics.
[mutual] Hims & Hers has a branded GLP-1 partnership with Novo Nordisk.
[mutual] Tempus AI has deepening partnerships with Daiichi Sankyo for AI-driven drug discovery.
[mutual] Tempus AI has deepening partnerships with Gilead for AI-driven drug discovery.
[mutual] Tempus AI has deepening partnerships with Merck for AI-driven drug discovery.
[mutual] Nurix Therapeutics has active collaborations with Gilead including profit-share opt-ins.
